AV1: F-18 Radiopharmaceutical for Imaging Amyloid Plaque

AV1：用于淀粉样斑块成像的 F-18 放射性药物

• 批准号: 6993822
• 负责人: DANIEL M SKOVRONSKY
• 金额: $ 10万
• 依托单位: AVID RADIOPHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2006-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6993822
• 关键词: Alzheimer' s disease; amyloid proteins; brain imaging /visualization /scanning; chemical synthesis; diagnosis design /evaluation; diagnosis quality /standard; drug design /synthesis /production; early diagnosis; fluorine; positron emission tomography; radiochemistry; radionuclide emission tomography; radiotracer

DESCRIPTION (provided by applicant): The long-term goal of this project is the development of radiopharmaceuticals for diagnosis of Alzheimer's disease (AD). The project is driven by the hypothesis that in vivo detection of amyloid plaques by positron emission computed tomography imaging (using radiolabeled amyloid binding probes) would allow for the early and definitive diagnosis of AD. A novel and promising F-18 labeled lead compound has been developed for this purpose, and will undergo further in-vivo evaluation. Phase I of this project will assess the feasibility of this approach by optimizing the production of the lead compound to enable preclinical testing and clinical trials. Specific aims of Phase I include: 1) Optimizing the synthesis of the novel cold compound; 2) Developing methods for radiochemical labeling of the compound. In Phase II we will conduct pharmacology and toxicology studies in support of an investigational new drug (IND) application. The compound will then undergo clinical development to yield a radiopharmaceutical for the evaluation and diagnosis of AD. Development of such a radiopharmaceutical will yield significant clinical, technological and scientific benefits that can be rapidly applied to improve the health and well being of the elderly population.

描述（由申请人提供）： 该项目的长期目标是开发用于诊断阿尔茨海默氏病（AD）的放射性药物。该项目是由以下假设驱动的：正电子发射计算机断层扫描成像（使用放射性标记的淀粉样蛋白结合探针）在体内检测淀粉样蛋白斑块将允许AD的早期和明确的诊断。为此，已经开发了一种新颖且有希望的F-18标记的铅化合物，并将进行进一步的体内评估。 该项目的第一阶段将通过优化铅化合物的生产以实现临床前测试和临床试验来评估这种方法的可行性。第一阶段的具体目的包括：1）优化新型冷化合物的合成； 2）开发化合物放射化学标记的方法。在第二阶段，我们将进行药理学和毒理学研究，以支持研究新药（IND）应用。 然后，该化合物将进行临床发育，以产生用于评估和诊断AD的放射性药物。这种放射性药物的发展将产生重要的临床，技术和科学益处，这些临床，技术和科学益处可以迅速应用于改善老年人群的健康和福祉。